Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 33

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 33
---
MARCH 31, 2025

Note 1 – Organization and Description
of Business

Jupiter Neurosciences, Inc. (the “Company”)
is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated in Delaware
in January 2016. The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation.
The product candidate, called JOTROL, has many potential indications of use for rare diseases. We are primarily targeting Mucopolysaccharidoses
Type 1, Friedreich’s Ataxia, and MELAS. In the larger disease areas, we are primarily targeting Parkinson’s Disease and Mild
Cognitive Impairment/early Alzheimer’s disease.

JOTROL has the potential to deliver a therapeutically
effective dose of resveratrol in the blood stream, using a unique patented micellar formulation, without causing gastrointestinal side
effects. We expect JOTROL, based on the results of our Phase I study, will resolve the major obstacle of resveratrol’s poor bioavailability,
which has been documented in various scientific articles describing previously conducted human trials with resveratrol as well as preclinical
trial results in mice and rats.

The Company’s activities and operations
include a project funded by the U.S. National Institute on Aging, an institute of the U.S. National Institutes of Health (“NIH”):
Safety and Pharmacokinetics of JOTROL for Alzheimer’s Disease, Federal Award Identification Number R44AG067907-01A1 (the “Award”).
The project encompassed a Phase 1 dose finding pharmacokinetics (“PK”) study which was completed before December 31, 2021.
The award end date was May 31, 2022. This Phase 1 PK study will be homogeneous for all indications where JOTROL will be used in Phase
II and Phase III clinical trials.

Initial Public Offering

In December 2024, the Company’s sold 2,750,000
shares of common stock, par value $0.0001 per share (“common stock”) at a price of $4.00 per share for gross proceeds of
$11 million before underwriting discounts and other related expenses in a registered initial public offering (the “IPO”).
In connection with the Public Offering, the Company’s common stock was registered under Section 12(b) of the Exchange Act and began
trading on The Nasdaq Capital